MasterCard Inc vs McKesson Corporation — how do they compare? MasterCard Inc trades at $574.4 (market cap $499.38B), while McKesson Corporation trades at $921.5 (market cap $106.14B). The key difference: MasterCard Inc is far larger — about 4.7× McKesson Corporation's market cap, and MasterCard Inc pays the higher dividend (0.61%). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and McKesson Corporation for 74 Days on average.
| MA | MCK | |
|---|---|---|
Market Cap | $499.38B | $106.14B |
Volume | 1,862,680 | 794,405 |
Sector | Financials | Health |
52-Week High | $599.86 | $995.69 |
52-Week Low | $471.55 | $725.17 |
Typical Hold Time | 134 Days | 74 Days |
Enterprise Value | $512.41B | $112.67B |
Dividend Yield | 0.61% | 0.41% |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $574.76, up 1.44% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with 46.3% net margins and 241.5% ROE, supported by growing institutional interest. Recent news highlights Mastercard's AI and digital payment initiatives, while analyst consensus remains strongly bullish with an $666.67 price target.
Outlook remains positive given earnings momentum and strategic positioning in digital payments, though competition from emerging payment technologies presents a key risk. The stock offers growth potential but requires monitoring of payment industry disruption and macroeconomic factors affecting consumer spending.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →